Cargando…

MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2

OBJECTIVE: Our study was designed to explore the association miR‐335‐5p and BCL2L2 and to investigate the influence of miR‐335‐5p/BCL2L2 axis on cisplatin‐resistant ovarian cancer cells. METHODS: Microarray analysis was used to determine differentially expressed microRNAs in primary and cisplatin‐re...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ruonan, Guo, Hailong, Lu, Shifen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143943/
https://www.ncbi.nlm.nih.gov/pubmed/30019389
http://dx.doi.org/10.1002/cam4.1682
_version_ 1783356069659017216
author Liu, Ruonan
Guo, Hailong
Lu, Shifen
author_facet Liu, Ruonan
Guo, Hailong
Lu, Shifen
author_sort Liu, Ruonan
collection PubMed
description OBJECTIVE: Our study was designed to explore the association miR‐335‐5p and BCL2L2 and to investigate the influence of miR‐335‐5p/BCL2L2 axis on cisplatin‐resistant ovarian cancer cells. METHODS: Microarray analysis was used to determine differentially expressed microRNAs in primary and cisplatin‐resistant A2780 cells. Cell function experiments were conducted to investigate the effect of miR‐335‐5p on the cisplatin sensitivity of A2780 cells. The targeted relationship between BCL2L2 mRNA and miR‐335‐5p was validated through luciferase assay. Tumor xenograft was performed to confirm the function of miR‐335‐5p in restoring the cisplatin sensitivity of the ovarian cancer cells. RESULTS: MiR‐335‐5p was lowly expressed in cisplatin‐resistant A2780 cells. Overexpression of miR‐335‐5p reduced cell survival and enhanced cisplatin‐induced cell apoptosis. BCL2L2 mRNA was a target of miR‐335‐5p, and silencing of BCL2L2 showed the similar results on the cell viability as miR‐335‐5p overexpression. CONCLUSION: Upregulation of miR‐335‐5p expression enhanced the cisplatin sensitivity of ovarian cancer cells through suppressing BCL2L2, suggesting the potential of miR‐335‐5p/BCL2L2 axis as a therapeutic target for the cisplatin resistance of patients with ovarian cancer.
format Online
Article
Text
id pubmed-6143943
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61439432018-09-24 MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2 Liu, Ruonan Guo, Hailong Lu, Shifen Cancer Med Cancer Biology OBJECTIVE: Our study was designed to explore the association miR‐335‐5p and BCL2L2 and to investigate the influence of miR‐335‐5p/BCL2L2 axis on cisplatin‐resistant ovarian cancer cells. METHODS: Microarray analysis was used to determine differentially expressed microRNAs in primary and cisplatin‐resistant A2780 cells. Cell function experiments were conducted to investigate the effect of miR‐335‐5p on the cisplatin sensitivity of A2780 cells. The targeted relationship between BCL2L2 mRNA and miR‐335‐5p was validated through luciferase assay. Tumor xenograft was performed to confirm the function of miR‐335‐5p in restoring the cisplatin sensitivity of the ovarian cancer cells. RESULTS: MiR‐335‐5p was lowly expressed in cisplatin‐resistant A2780 cells. Overexpression of miR‐335‐5p reduced cell survival and enhanced cisplatin‐induced cell apoptosis. BCL2L2 mRNA was a target of miR‐335‐5p, and silencing of BCL2L2 showed the similar results on the cell viability as miR‐335‐5p overexpression. CONCLUSION: Upregulation of miR‐335‐5p expression enhanced the cisplatin sensitivity of ovarian cancer cells through suppressing BCL2L2, suggesting the potential of miR‐335‐5p/BCL2L2 axis as a therapeutic target for the cisplatin resistance of patients with ovarian cancer. John Wiley and Sons Inc. 2018-07-17 /pmc/articles/PMC6143943/ /pubmed/30019389 http://dx.doi.org/10.1002/cam4.1682 Text en © 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Cancer Biology
Liu, Ruonan
Guo, Hailong
Lu, Shifen
MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
title MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
title_full MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
title_fullStr MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
title_full_unstemmed MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
title_short MiR‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting BCL2L2
title_sort mir‐335‐5p restores cisplatin sensitivity in ovarian cancer cells through targeting bcl2l2
topic Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6143943/
https://www.ncbi.nlm.nih.gov/pubmed/30019389
http://dx.doi.org/10.1002/cam4.1682
work_keys_str_mv AT liuruonan mir3355prestorescisplatinsensitivityinovariancancercellsthroughtargetingbcl2l2
AT guohailong mir3355prestorescisplatinsensitivityinovariancancercellsthroughtargetingbcl2l2
AT lushifen mir3355prestorescisplatinsensitivityinovariancancercellsthroughtargetingbcl2l2